Another study indicates that evodiamine can inhibit prostate cancer growth by reducing lactylation of hypoxia‐inducible factor 1 alpha (HIF1α) in prostate cancer cells, a finding corroborated by animal experiments. Here, HIF1A is linked to prostate carcinoma.